Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-05-09

FDA Approved: TREXIMET — Supplemental Application (Currax Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved a supplemental application for Treximet, the combination of sumatriptan succinate and naproxen sodium, submitted by Currax Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TREXIMET (sumatriptan succinate and naproxen sodium)

Snippet

SUPPL AP for TREXIMET (SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM)